XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:
XOFLUZA is also indicated for post-exposure prophylaxis (PEP) of influenza in patients 12 years of age and older following contact with an individual who has influenza.
Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.
XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.
Warnings and Precautions
Hypersensitivity: Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA. Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.
Risk of bacterial Infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.
The most common adverse reactions (≥1%) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).
The most common adverse reaction in a clinical study for
post-exposure prophylaxis (PEP) was nasopharyngitis (6%).
Polyvalent cations: Coadministration with polyvalent
cation-containing products may decrease plasma concentrations of
baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration
of XOFLUZA with dairy products, calcium-fortified beverages,
polyvalent cation-containing laxatives, antacids, or oral supplements
(e.g., calcium, iron, magnesium, selenium, or zinc).
Vaccines: The concurrent use of XOFLUZA with intranasal live
attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent
administration of antiviral drugs may inhibit viral replication of
LAIV and, thereby, decrease the effectiveness of LAIV vaccination.
Interactions between inactivated influenza vaccines and XOFLUZA have
not been evaluated.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.